About
HRA Pharma, SA develops and commercializes drugs, devices, and services in the therapeutic areas of reproductive health and endocrine diseases. It offers reproductive health products, which include Norlevo for emergency contraception; Cicatridine for vaginitis and vaginal injury; Delidose, Divina, and Duova for HRT; GyMiso for cervical ripening; and Mona Lisa, a copper contraceptive intrauterine device, as well as endocrinal products that include Lysodren and Lysosafe for adrenal cancer. The company also provides Bemedrex for asthma; Deprenyl for Parkinson's disease; and information and associated services for healthcare providers and other users. In addition, its development pipeline comprises ella/ellaOne, an emergency contraceptive pill; UPA UF, a treatment for uterine fibroids; UPA contraceptive products; Mifedren, a product candidate for a subset of Cushing's syndromes caused by ectopic ACTH(1) secretion; and cell-based therapies for muscle regeneration. The company distributes an
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 2,833 investors are based in Paris, Ile-de-France, France.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Paris, France
Contact Information
Find more investors like HRA
Search Investors